Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Kolibash

Clinical Cardiac Electrophysiology Weirton, WV Medical Doctor

NPI 1043228414 CMS profile 1501

243 Three Springs Dr Ste 5A, Weirton, WV 26062

Open in the dashboard

General payments

$42,241

595 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Kolibash of Weirton, WV is reported in the CMS Open Payments database as having received $42,241 across 595 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,276 59
2024 General $6,383 69
2023 General $7,805 93
2022 General $3,295 75
2021 General $2,376 86
2020 General $6,823 81
2019 General $11,284 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Kolibash
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Christopher Kolibash were reported at $4,276. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Christopher Kolibash Clinical Cardiac Electrophysiology median Middle half National median
2019 $11,284 $2,361 $585–$8,260 $163
2020 $6,823 $993 $247–$4,351 $114
2021 $2,376 $1,185 $326–$4,739 $132
2022 $3,295 $2,073 $554–$6,789 $149
2023 $7,805 $2,568 $759–$8,159 $160
2024 $6,383 $2,557 $703–$7,403 $164
2025 $4,276 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $18,395 279 payments
  2. Boston Scientific Corporation $9,219 134 payments
  3. Medtronic, Inc. $5,045 60 payments
  4. Atricure, Inc. $2,997 19 payments
  5. Medtronic Vascular, Inc. $2,925 31 payments
  6. Biotronik Inc. $1,467 11 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $777 17 payments
  8. Impulse Dynamics (USA) Inc. $418 6 payments
  9. Janssen Pharmaceuticals, Inc $199 12 payments
  10. E.R. Squibb & Sons, L.L.C. $151 3 payments
  11. Other $649 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,409 507 payments
  2. Travel and Lodging $16,956 63 payments
  3. Consulting Fee $4,861 20 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 4 payments
  5. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $2,838 17 payments
  2. EMBLEM $2,687 17 payments
  3. Arctic Front $2,588 12 payments
  4. AVEIR Cardiac Rhythm Management $2,541 13 payments
  5. AVEIR Cardiac Rhythm Management $2,353 25 payments
  6. Allure CRT Pacemaker $1,790 6 payments
  7. ACCENT $1,507 7 payments
  8. Endurity Pacemaker $1,275 6 payments
  9. AVEIR Cardiac Rhythm Management $1,273 8 payments
  10. General - Therapies $1,267 5 payments
  11. Other $17,037 444 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,866

Median for Internal Medicine: 777

Drug cost

$578,355

Median for Internal Medicine: $73,373

Branded share of claims

36.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 470 $340,772
Xarelto Rivaroxaban Brand 104 $81,820
Dofetilide Generic 414 $79,527
Multaq Dronedarone Hcl Brand 54 $47,112
Flecainide Acetate Generic 232 $8,450
Metoprolol Succinate Generic 361 $3,960
Mexiletine Hcl Generic 46 $3,713
Doxycycline Monohydrate Generic 302 $2,163
Sotalol Sotalol Hcl Brand 108 $1,871
Amiodarone Hcl Generic 198 $1,765

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$379,488

Medicare's payments for the services billed

Medicare patients

1,336

Average age 76

Services billed

7,328

560 women, 776 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 70%
Ischemic heart disease 59%
Arthritis 53%
Heart failure 48%
Diabetes 40%
Chronic kidney disease 38%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $21
$21 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $15
$15 104 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

595 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record